Neuroprotective Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions. 
The global market for Neuroprotective Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

Factors expected to drive market growth include increasing prevalence of neurological disorders. Neurological diseases are the leading cause of disability and death worldwide. The “big three” neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, have resulted in significant increases in morbidity and mortality in the elderly population worldwide. Neuroprotective drugs are those that help maintain the structure and function of neurons. Neuroprotective drugs have the potential to reduce stroke deaths by 6 million per year. According to data updated by the World Health Organization in February 2022, approximately 50 million people worldwide suffer from epilepsy every year.

Alzheimer's disease segment is expected to hold major market share in the neuroprotective agents market
The incidence of Alzheimer's disease has been increasing and is expected to continue to increase in the coming decades. According to statistics from the World Health Organization, nearly 50 million people worldwide were suffering from Alzheimer's disease and other dementias in 2020, and this number is expected to exceed 152 million by 2050. Additionally, Alzheimer's disease progression increases with age and is the fifth largest contributor to the global disease burden, with the global disease burden exceeding 1 Trillions of dollars.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuroprotective Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Neuroprotective Drugs by region & country, by Type, and by Application.

The Neuroprotective Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroprotective Drugs.

Market Segmentation

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neuroprotective Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Neuroprotective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Neuroprotective Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

 1 Market Overview
    1.1 Neuroprotective Drugs Product Introduction
    1.2 Global Neuroprotective Drugs Market Size Forecast
        1.2.1 Global Neuroprotective Drugs Sales Value (2019-2030)
        1.2.2 Global Neuroprotective Drugs Sales Volume (2019-2030)
        1.2.3 Global Neuroprotective Drugs Sales Price (2019-2030)
    1.3 Neuroprotective Drugs Market Trends & Drivers
        1.3.1 Neuroprotective Drugs Industry Trends
        1.3.2 Neuroprotective Drugs Market Drivers & Opportunity
        1.3.3 Neuroprotective Drugs Market Challenges
        1.3.4 Neuroprotective Drugs Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Neuroprotective Drugs Players Revenue Ranking (2023)
    2.2 Global Neuroprotective Drugs Revenue by Company (2019-2024)
    2.3 Global Neuroprotective Drugs Players Sales Volume Ranking (2023)
    2.4 Global Neuroprotective Drugs Sales Volume by Company Players (2019-2024)
    2.5 Global Neuroprotective Drugs Average Price by Company (2019-2024)
    2.6 Key Manufacturers Neuroprotective Drugs Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers Neuroprotective Drugs Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of Neuroprotective Drugs
    2.9 Neuroprotective Drugs Market Competitive Analysis
        2.9.1 Neuroprotective Drugs Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by Neuroprotective Drugs Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroprotective Drugs as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Cholinesterase inhibitors
        3.1.2 Anti-inflammatory
        3.1.3 Others
    3.2 Global Neuroprotective Drugs Sales Value by Type
        3.2.1 Global Neuroprotective Drugs Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Neuroprotective Drugs Sales Value, by Type (2019-2030)
        3.2.3 Global Neuroprotective Drugs Sales Value, by Type (%) (2019-2030)
    3.3 Global Neuroprotective Drugs Sales Volume by Type
        3.3.1 Global Neuroprotective Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global Neuroprotective Drugs Sales Volume, by Type (2019-2030)
        3.3.3 Global Neuroprotective Drugs Sales Volume, by Type (%) (2019-2030)
    3.4 Global Neuroprotective Drugs Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Alzheimer's disease
        4.1.2 Parkinson's disease
        4.1.3 Others
    4.2 Global Neuroprotective Drugs Sales Value by Application
        4.2.1 Global Neuroprotective Drugs Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Neuroprotective Drugs Sales Value, by Application (2019-2030)
        4.2.3 Global Neuroprotective Drugs Sales Value, by Application (%) (2019-2030)
    4.3 Global Neuroprotective Drugs Sales Volume by Application
        4.3.1 Global Neuroprotective Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global Neuroprotective Drugs Sales Volume, by Application (2019-2030)
        4.3.3 Global Neuroprotective Drugs Sales Volume, by Application (%) (2019-2030)
    4.4 Global Neuroprotective Drugs Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global Neuroprotective Drugs Sales Value by Region
        5.1.1 Global Neuroprotective Drugs Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Neuroprotective Drugs Sales Value by Region (2019-2024)
        5.1.3 Global Neuroprotective Drugs Sales Value by Region (2025-2030)
        5.1.4 Global Neuroprotective Drugs Sales Value by Region (%), (2019-2030)
    5.2 Global Neuroprotective Drugs Sales Volume by Region
        5.2.1 Global Neuroprotective Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global Neuroprotective Drugs Sales Volume by Region (2019-2024)
        5.2.3 Global Neuroprotective Drugs Sales Volume by Region (2025-2030)
        5.2.4 Global Neuroprotective Drugs Sales Volume by Region (%), (2019-2030)
    5.3 Global Neuroprotective Drugs Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America Neuroprotective Drugs Sales Value, 2019-2030
        5.4.2 North America Neuroprotective Drugs Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe Neuroprotective Drugs Sales Value, 2019-2030
        5.5.2 Europe Neuroprotective Drugs Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific Neuroprotective Drugs Sales Value, 2019-2030
        5.6.2 Asia Pacific Neuroprotective Drugs Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America Neuroprotective Drugs Sales Value, 2019-2030
        5.7.2 South America Neuroprotective Drugs Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Neuroprotective Drugs Sales Value, 2019-2030
        5.8.2 Middle East & Africa Neuroprotective Drugs Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Neuroprotective Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Neuroprotective Drugs Sales Value
        6.2.1 Key Countries/Regions Neuroprotective Drugs Sales Value, 2019-2030
        6.2.2 Key Countries/Regions Neuroprotective Drugs Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States Neuroprotective Drugs Sales Value, 2019-2030
        6.3.2 United States Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Neuroprotective Drugs Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Neuroprotective Drugs Sales Value, 2019-2030
        6.4.2 Europe Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Neuroprotective Drugs Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Neuroprotective Drugs Sales Value, 2019-2030
        6.5.2 China Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Neuroprotective Drugs Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Neuroprotective Drugs Sales Value, 2019-2030
        6.6.2 Japan Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Neuroprotective Drugs Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Neuroprotective Drugs Sales Value, 2019-2030
        6.7.2 South Korea Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Neuroprotective Drugs Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Neuroprotective Drugs Sales Value, 2019-2030
        6.8.2 Southeast Asia Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Neuroprotective Drugs Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Neuroprotective Drugs Sales Value, 2019-2030
        6.9.2 India Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Neuroprotective Drugs Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Genervon
        7.1.1 Genervon Company Information
        7.1.2 Genervon Introduction and Business Overview
        7.1.3 Genervon Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Genervon Neuroprotective Drugs Product Offerings
        7.1.5 Genervon Recent Development
    7.2 NeuroVive Pharmaceutical
        7.2.1 NeuroVive Pharmaceutical Company Information
        7.2.2 NeuroVive Pharmaceutical Introduction and Business Overview
        7.2.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 NeuroVive Pharmaceutical Neuroprotective Drugs Product Offerings
        7.2.5 NeuroVive Pharmaceutical Recent Development
    7.3 Ceregene
        7.3.1 Ceregene Company Information
        7.3.2 Ceregene Introduction and Business Overview
        7.3.3 Ceregene Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 Ceregene Neuroprotective Drugs Product Offerings
        7.3.5 Ceregene Recent Development
    7.4 BHR Pharma
        7.4.1 BHR Pharma Company Information
        7.4.2 BHR Pharma Introduction and Business Overview
        7.4.3 BHR Pharma Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 BHR Pharma Neuroprotective Drugs Product Offerings
        7.4.5 BHR Pharma Recent Development
    7.5 Neuren Pharmaceuticals
        7.5.1 Neuren Pharmaceuticals Company Information
        7.5.2 Neuren Pharmaceuticals Introduction and Business Overview
        7.5.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Neuren Pharmaceuticals Neuroprotective Drugs Product Offerings
        7.5.5 Neuren Pharmaceuticals Recent Development
    7.6 Allon therapeutics
        7.6.1 Allon therapeutics Company Information
        7.6.2 Allon therapeutics Introduction and Business Overview
        7.6.3 Allon therapeutics Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.6.4 Allon therapeutics Neuroprotective Drugs Product Offerings
        7.6.5 Allon therapeutics Recent Development
    7.7 Bionure
        7.7.1 Bionure Company Information
        7.7.2 Bionure Introduction and Business Overview
        7.7.3 Bionure Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.7.4 Bionure Neuroprotective Drugs Product Offerings
        7.7.5 Bionure Recent Development
    7.8 AstraZeneca
        7.8.1 AstraZeneca Company Information
        7.8.2 AstraZeneca Introduction and Business Overview
        7.8.3 AstraZeneca Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.8.4 AstraZeneca Neuroprotective Drugs Product Offerings
        7.8.5 AstraZeneca Recent Development
    7.9 Biogen
        7.9.1 Biogen Company Information
        7.9.2 Biogen Introduction and Business Overview
        7.9.3 Biogen Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.9.4 Biogen Neuroprotective Drugs Product Offerings
        7.9.5 Biogen Recent Development
    7.10 Merck KGaA
        7.10.1 Merck KGaA Company Information
        7.10.2 Merck KGaA Introduction and Business Overview
        7.10.3 Merck KGaA Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.10.4 Merck KGaA Neuroprotective Drugs Product Offerings
        7.10.5 Merck KGaA Recent Development
    7.11 Teva Pharmaceutical Industries Ltd
        7.11.1 Teva Pharmaceutical Industries Ltd Company Information
        7.11.2 Teva Pharmaceutical Industries Ltd Introduction and Business Overview
        7.11.3 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.11.4 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Offerings
        7.11.5 Teva Pharmaceutical Industries Ltd Recent Development
    7.12 Novartis
        7.12.1 Novartis Company Information
        7.12.2 Novartis Introduction and Business Overview
        7.12.3 Novartis Neuroprotective Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.12.4 Novartis Neuroprotective Drugs Product Offerings
        7.12.5 Novartis Recent Development

 8 Industry Chain Analysis
    8.1 Neuroprotective Drugs Industrial Chain
    8.2 Neuroprotective Drugs Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Neuroprotective Drugs Sales Model
        8.5.2 Sales Channel
        8.5.3 Neuroprotective Drugs Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Neuroprotective Drugs Market Trends
    Table 2. Neuroprotective Drugs Market Drivers & Opportunity
    Table 3. Neuroprotective Drugs Market Challenges
    Table 4. Neuroprotective Drugs Market Restraints
    Table 5. Global Neuroprotective Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Neuroprotective Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Global Neuroprotective Drugs Sales Volume by Company (2019-2024) & (MT)
    Table 8. Global Neuroprotective Drugs Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Neuroprotective Drugs Price by Company (2019-2024) & (USD/Kg)
    Table 10. Key Manufacturers Neuroprotective Drugs Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Neuroprotective Drugs Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Neuroprotective Drugs
    Table 13. Global Neuroprotective Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroprotective Drugs as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Neuroprotective Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Neuroprotective Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Neuroprotective Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Neuroprotective Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Neuroprotective Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Neuroprotective Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (MT)
    Table 22. Global Neuroprotective Drugs Sales Volume by Type (2019-2024) & (MT)
    Table 23. Global Neuroprotective Drugs Sales Volume by Type (2025-2030) & (MT)
    Table 24. Global Neuroprotective Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Neuroprotective Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Neuroprotective Drugs Price by Type (2019-2024) & (USD/Kg)
    Table 27. Global Neuroprotective Drugs Price by Type (2025-2030) & (USD/Kg)
    Table 28. Global Neuroprotective Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Neuroprotective Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Neuroprotective Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Neuroprotective Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Neuroprotective Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Neuroprotective Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (MT)
    Table 34. Global Neuroprotective Drugs Sales Volume by Application (2019-2024) & (MT)
    Table 35. Global Neuroprotective Drugs Sales Volume by Application (2025-2030) & (MT)
    Table 36. Global Neuroprotective Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Neuroprotective Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Neuroprotective Drugs Price by Application (2019-2024) & (USD/Kg)
    Table 39. Global Neuroprotective Drugs Price by Application (2025-2030) & (USD/Kg)
    Table 40. Global Neuroprotective Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Neuroprotective Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Neuroprotective Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Neuroprotective Drugs Sales Value by Region (2019-2024) & (%)
    Table 44. Global Neuroprotective Drugs Sales Value by Region (2025-2030) & (%)
    Table 45. Global Neuroprotective Drugs Sales Volume by Region (MT): 2019 VS 2023 VS 2030
    Table 46. Global Neuroprotective Drugs Sales Volume by Region (2019-2024) & (MT)
    Table 47. Global Neuroprotective Drugs Sales Volume by Region (2025-2030) & (MT)
    Table 48. Global Neuroprotective Drugs Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Neuroprotective Drugs Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Neuroprotective Drugs Average Price by Region (2019-2024) & (USD/Kg)
    Table 51. Global Neuroprotective Drugs Average Price by Region (2025-2030) & (USD/Kg)
    Table 52. Key Countries/Regions Neuroprotective Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Neuroprotective Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Neuroprotective Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Neuroprotective Drugs Sales Volume, (2019-2024) & (MT)
    Table 56. Key Countries/Regions Neuroprotective Drugs Sales Volume, (2025-2030) & (MT)
    Table 57. Genervon Company Information
    Table 58. Genervon Introduction and Business Overview
    Table 59. Genervon Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 60. Genervon Neuroprotective Drugs Product Offerings
    Table 61. Genervon Recent Development
    Table 62. NeuroVive Pharmaceutical Company Information
    Table 63. NeuroVive Pharmaceutical Introduction and Business Overview
    Table 64. NeuroVive Pharmaceutical Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 65. NeuroVive Pharmaceutical Neuroprotective Drugs Product Offerings
    Table 66. NeuroVive Pharmaceutical Recent Development
    Table 67. Ceregene Company Information
    Table 68. Ceregene Introduction and Business Overview
    Table 69. Ceregene Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 70. Ceregene Neuroprotective Drugs Product Offerings
    Table 71. Ceregene Recent Development
    Table 72. BHR Pharma Company Information
    Table 73. BHR Pharma Introduction and Business Overview
    Table 74. BHR Pharma Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 75. BHR Pharma Neuroprotective Drugs Product Offerings
    Table 76. BHR Pharma Recent Development
    Table 77. Neuren Pharmaceuticals Company Information
    Table 78. Neuren Pharmaceuticals Introduction and Business Overview
    Table 79. Neuren Pharmaceuticals Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 80. Neuren Pharmaceuticals Neuroprotective Drugs Product Offerings
    Table 81. Neuren Pharmaceuticals Recent Development
    Table 82. Allon therapeutics Company Information
    Table 83. Allon therapeutics Introduction and Business Overview
    Table 84. Allon therapeutics Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 85. Allon therapeutics Neuroprotective Drugs Product Offerings
    Table 86. Allon therapeutics Recent Development
    Table 87. Bionure Company Information
    Table 88. Bionure Introduction and Business Overview
    Table 89. Bionure Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 90. Bionure Neuroprotective Drugs Product Offerings
    Table 91. Bionure Recent Development
    Table 92. AstraZeneca Company Information
    Table 93. AstraZeneca Introduction and Business Overview
    Table 94. AstraZeneca Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 95. AstraZeneca Neuroprotective Drugs Product Offerings
    Table 96. AstraZeneca Recent Development
    Table 97. Biogen Company Information
    Table 98. Biogen Introduction and Business Overview
    Table 99. Biogen Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 100. Biogen Neuroprotective Drugs Product Offerings
    Table 101. Biogen Recent Development
    Table 102. Merck KGaA Company Information
    Table 103. Merck KGaA Introduction and Business Overview
    Table 104. Merck KGaA Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 105. Merck KGaA Neuroprotective Drugs Product Offerings
    Table 106. Merck KGaA Recent Development
    Table 107. Teva Pharmaceutical Industries Ltd Company Information
    Table 108. Teva Pharmaceutical Industries Ltd Introduction and Business Overview
    Table 109. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 110. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Offerings
    Table 111. Teva Pharmaceutical Industries Ltd Recent Development
    Table 112. Novartis Company Information
    Table 113. Novartis Introduction and Business Overview
    Table 114. Novartis Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
    Table 115. Novartis Neuroprotective Drugs Product Offerings
    Table 116. Novartis Recent Development
    Table 117. Key Raw Materials Lists
    Table 118. Raw Materials Key Suppliers Lists
    Table 119. Neuroprotective Drugs Downstream Customers
    Table 120. Neuroprotective Drugs Distributors List
    Table 121. Research Programs/Design for This Report
    Table 122. Key Data Information from Secondary Sources
    Table 123. Key Data Information from Primary Sources
List of Figures
    Figure 1. Neuroprotective Drugs Product Picture
    Figure 2. Global Neuroprotective Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Neuroprotective Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Neuroprotective Drugs Sales Volume (2019-2030) & (MT)
    Figure 5. Global Neuroprotective Drugs Sales Price (2019-2030) & (USD/Kg)
    Figure 6. Neuroprotective Drugs Report Years Considered
    Figure 7. Global Neuroprotective Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Neuroprotective Drugs Players Sales Volume Ranking (2023) & (MT)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Neuroprotective Drugs Revenue in 2023
    Figure 10. Neuroprotective Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Cholinesterase inhibitors Picture
    Figure 12. Anti-inflammatory Picture
    Figure 13. Others Picture
    Figure 14. Global Neuroprotective Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Neuroprotective Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 16. Global Neuroprotective Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (MT)
    Figure 17. Global Neuroprotective Drugs Sales Volume Market Share by Type, 2023 & 2030
    Figure 18. Global Neuroprotective Drugs Price by Type (2019-2030) & (USD/Kg)
    Figure 19. Product Picture of Alzheimer's disease
    Figure 20. Product Picture of Parkinson's disease
    Figure 21. Product Picture of Others
    Figure 22. Global Neuroprotective Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 23. Global Neuroprotective Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 24. Global Neuroprotective Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (MT)
    Figure 25. Global Neuroprotective Drugs Sales Volume Market Share by Application, 2023 & 2030
    Figure 26. Global Neuroprotective Drugs Price by Application (2019-2030) & (USD/Kg)
    Figure 27. North America Neuroprotective Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 28. North America Neuroprotective Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 29. Europe Neuroprotective Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 30. Europe Neuroprotective Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 31. Asia Pacific Neuroprotective Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Neuroprotective Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 33. South America Neuroprotective Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 34. South America Neuroprotective Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 35. Middle East & Africa Neuroprotective Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 36. Middle East & Africa Neuroprotective Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 37. Key Countries/Regions Neuroprotective Drugs Sales Value (%), (2019-2030)
    Figure 38. Key Countries/Regions Neuroprotective Drugs Sales Volume (%), (2019-2030)
    Figure 39. United States Neuroprotective Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 40. United States Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 41. United States Neuroprotective Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 42. Europe Neuroprotective Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Europe Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 44. Europe Neuroprotective Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 45. China Neuroprotective Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 46. China Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 47. China Neuroprotective Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 48. Japan Neuroprotective Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 49. Japan Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 50. Japan Neuroprotective Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 51. South Korea Neuroprotective Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 52. South Korea Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 53. South Korea Neuroprotective Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 54. Southeast Asia Neuroprotective Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 55. Southeast Asia Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 56. Southeast Asia Neuroprotective Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 57. India Neuroprotective Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 58. India Neuroprotective Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 59. India Neuroprotective Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 60. Neuroprotective Drugs Industrial Chain
    Figure 61. Neuroprotective Drugs Manufacturing Cost Structure
    Figure 62. Channels of Distribution (Direct Sales, and Distribution)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed

Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions. 
The global market for Neuroprotective Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

Factors expected to drive market growth include increasing prevalence of neurological disorders. Neurological diseases are the leading cause of disability and death worldwide. The “big three” neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, have resulted in significant increases in morbidity and mortality in the elderly population worldwide. Neuroprotective drugs are those that help maintain the structure and function of neurons. Neuroprotective drugs have the potential to reduce stroke deaths by 6 million per year. According to data updated by the World Health Organization in February 2022, approximately 50 million people worldwide suffer from epilepsy every year.

Alzheimer's disease segment is expected to hold major market share in the neuroprotective agents market
The incidence of Alzheimer's disease has been increasing and is expected to continue to increase in the coming decades. According to statistics from the World Health Organization, nearly 50 million people worldwide were suffering from Alzheimer's disease and other dementias in 2020, and this number is expected to exceed 152 million by 2050. Additionally, Alzheimer's disease progression increases with age and is the fifth largest contributor to the global disease burden, with the global disease burden exceeding 1 Trillions of dollars.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuroprotective Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Neuroprotective Drugs by region & country, by Type, and by Application.

The Neuroprotective Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroprotective Drugs.

Market Segmentation

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neuroprotective Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Neuroprotective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Neuroprotective Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.